Although the relative reduction of CD38 expression linked with low NSD2 could constitute a concern for anti-CD38 monoclonal antibody targeting, the higher expression of MHC II genes could improve immune effector based TCE approaches to t(4;14) myeloma in context of future NSD2 targeting therapy. Here, NSD2 is linked to plasma cell myeloma.